Hepatitis B immune globulin - Emergent BioSolutions

Drug Profile

Hepatitis B immune globulin - Emergent BioSolutions

Alternative Names: HepaGam B; ImmunoGam

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cangene Corporation
  • Developer Aptevo Therapeutics; Emergent BioSolutions; Saol Therapeutics
  • Class Antivirals; Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis B
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B

Most Recent Events

  • 28 Sep 2017 Saol Therapeutics completes the acquisition of Hepatitis B immunoglobulin from Aptevo Therapeutics
  • 31 Aug 2017 Saol Therapeutics enters agreement to acquire Hepatitis B immune globulin from Aptevo Therapeutics
  • 01 Aug 2016 Emergent BioSolutions forms a spin-off Aptevo Therapeutics for its oncology and haematology products
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top